A carregar...
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection
AIM: To evaluate efficacy/safety of hepatitis C virus (HCV) protease inhibitor boceprevir with pegylated interferon (PEG-IFN) alfa and weight-based ribavirin (RBV) in a phase 3 trial. METHODS: A prospective, multicenter, phase 3, open-label, single-arm study of PEG-IFN alfa, weight-based RBV, and bo...
Na minha lista:
| Publicado no: | World J Hepatol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Inc
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5295161/ https://ncbi.nlm.nih.gov/pubmed/28217259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v9.i4.217 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|